Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Remote Monitoring of Diabetes in Young Children With Type 1 Diabetes

7. november 2019 oppdatert av: Korey Hood, Stanford University
The primary objective of this project is to examine the impact of a continuous glucose monitoring (CGM) intervention on health and psychological outcomes in young children with type 1 diabetes (T1D).

Studieoversikt

Studietype

Intervensjonell

Registrering (Faktiske)

92

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • California
      • Stanford, California, Forente stater, 94305
        • Stanford University
    • Colorado
      • Aurora, Colorado, Forente stater, 80045
        • University of Colorado
    • Florida
      • Tampa, Florida, Forente stater, 33620
        • University of South Florida
    • Indiana
      • Indianapolis, Indiana, Forente stater, 46202
        • Indiana University

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

2 år til 6 år (Barn)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

To be eligible for the study, a child must meet the following criteria:

  1. Diagnosis of type 1 diabetes according to American Diabetes Association diagnostic criteria
  2. Time since diagnosis of at least six months
  3. Age between 2 and 6 years at enrollment
  4. Parental consent to participate in the study
  5. No severe medical conditions, which in the opinion of the investigators are likely to hinder participation in this clinical trial.
  6. If current use of CGM, A1c has to be above 7.5%; value obtained within 3 months of enrollment
  7. Own and use an iPhone, or be willing/able to carry a study-supplied wi-fi enabled iPod

To be eligible for the study, a parent must meet the following criteria:

  1. Parent or legal guardian of a child with type 1 diabetes meeting the "child" criteria outlined above
  2. Age of 18.0 years or older
  3. Parent comprehends written English
  4. Parent understands the study protocol and signs the informed consent document
  5. Parent has access to a personal computer to upload diabetes devices and send to research team

The presence of any of the following is an exclusion for the study:

  1. Child has a medical disorder that in the judgment of the investigator will interfere with completion of any aspect of the protocol (e.g., pregnancy, kidney disease, adrenal insufficiency, skin condition that may hinder sensor application).
  2. Child has a neurologic disorder that in the judgment of the investigator will affect completion of the protocol
  3. Current use of oral glucocorticoids or other medications, which in the judgment of the investigator would be a contraindication to participation in the study
  4. Child is unable to completely avoid acetaminophen for duration of study

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Faktoriell oppgave
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Nødreduksjon
Identifiser og reduser foreldrenes plagesymptomer og bekymringer. Gi strategier for å få sosial støtte.
Utdanning og opplæring for å redusere nød
Eksperimentell: Developmental Demands
Provide education on using diabetes technology in various settings and formats in this age group, and increase ability for real-time problem-solving.
Education and training related to use of CGM in this age group
Eksperimentell: Remote Monitoring
Optimize the use of remote monitoring by focusing on situational demands and problem solving.
Education and training on the use of remote monitoring
Eksperimentell: Fear of Hypoglycemia
Decrease fear of hypoglycemia, particularly focusing on overnight glycemic control.
Education and training on reducing fear of hypoglycemia
Placebo komparator: No Intervention
Serves as the control group comparator. No intervention provided.
No intervention - serves as the control group

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Time spent in blood glucose range
Tidsramme: Change over 6 months
Increasingly it is recognized that the percent time spent in a target blood glucose range, which is set by the American Diabetes Association, is an important outcome. This measure will be used as a primary outcome and derived from objective data downloads.
Change over 6 months
Pediatric Quality of Life Inventory
Tidsramme: Change over 6 months
This is a measure of health-related quality of life. It is used to understand the broader impact on quality of life which includes social, psychological, and health aspects of daily living.
Change over 6 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
A1c
Tidsramme: Change over 6 months
The hemoglobin A1c value is a biologic measure of the glycemia that is the gold standard measure of "control" of diabetes. Collected through a blood sample.
Change over 6 months
Problem Areas in Diabetes
Tidsramme: Change over 6 months
This measure captures areas that are reported as problems for people with diabetes. Participants in the study report on daily problems with diabetes via this measure.
Change over 6 months
Diabetes Distress Scale
Tidsramme: Change over 6 months
This measure is widely used to capture the psychological distress experienced in relation to diabetes.
Change over 6 months
Patient Health Questionnaire 9
Tidsramme: Change over 6 months
This is a widely used measure that captures depressive symptoms. It is reported by the participants.
Change over 6 months
State-Trait Anxiety Inventory
Tidsramme: Change over 6 months
This is a widely used measure of anxiety symptoms. It is reported by the participant.
Change over 6 months
Pittsburgh Sleep Quality Index
Tidsramme: Change over 6 months
This questionnaire measures the degree to which sleep is disrupted and the quality of sleep experienced by participants.
Change over 6 months
Hypoglycemic Fear Survey
Tidsramme: Change over 6 months
People with diabetes worry about hypoglycemia. This measure captures those worries and is reported by participants.
Change over 6 months
Hypoglycemic Confidence Questionnaire
Tidsramme: Change over 6 months
Hypoglycemia needs to be managed in various daily situations. This questionnaire captures confidence of the participants in those various situations.
Change over 6 months
Glucose Monitoring System Satisfaction Survey
Tidsramme: Change over 6 months
This a measure used to capture overall satisfaction with glucose monitoring devices used by participants.
Change over 6 months
General and diabetes-specific technology use
Tidsramme: Change over 6 months
This measure has questions on attitudes and use of various general technologies (e.g., smartphone) and diabetes devices.
Change over 6 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Linda DiMeglio, MD, Indiana University
  • Hovedetterforsker: Kimberly Driscoll, PhD, University of Colorado, Denver
  • Hovedetterforsker: Henry Rodriguez, MD, University of South Florida

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

15. august 2016

Primær fullføring (Faktiske)

1. april 2019

Studiet fullført (Faktiske)

1. april 2019

Datoer for studieregistrering

Først innsendt

25. juli 2016

Først innsendt som oppfylte QC-kriteriene

25. juli 2016

Først lagt ut (Anslag)

28. juli 2016

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

12. november 2019

Siste oppdatering sendt inn som oppfylte QC-kriteriene

7. november 2019

Sist bekreftet

1. november 2019

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Kliniske studier på Type 1 diabetes mellitus

Kliniske studier på Nødreduksjon

3
Abonnere